Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction.

Trial Profile

A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Famciclovir (Primary)
  • Indications Herpes genitalis
  • Focus Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Novartis

Most Recent Events

  • 26 Apr 2012 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
  • 26 Apr 2012 Actual initiation date (Jun 2003) added as reported by ClinicalTrials.gov.
  • 26 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00219310).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top